 Safety evaluations will be based mainly on the frequency of adverse events, including all of the serious adverse events. Adverse events will be summarized presenting per each treatment group the number and percentage of patients who have presented any adverse event whatever, an adverse event in a specific body system and a specific adverse event. Any other information collected i.e., the severity or correlation with the study drug will be codified as appropriate. 